Insider Selling: Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells $136,890.00 in Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 3,000 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $45.63, for a total value of $136,890.00. Following the transaction, the chief executive officer now directly owns 37,916 shares in the company, valued at approximately $1,730,107.08. This represents a 7.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas David Hull III also recently made the following trade(s):

• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The shares were sold at an average price of $48.53, for a total value of $10,336.89.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The shares were sold at an average price of $60.08, for a total value of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total transaction of $126,020.00.

Kewaunee Scientific Trading Down 1.5 %

NASDAQ:KEQU opened at $40.00 on Thursday. The business’s 50-day moving average is $56.58 and its two-hundred day moving average is $47.50. The firm has a market capitalization of $114.20 million, a PE ratio of 6.34 and a beta of 0.71. Kewaunee Scientific Co. has a 12 month low of $30.82 and a 12 month high of $71.33. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13.

Kewaunee Scientific (NASDAQ:KEQU) last released its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 EPS for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The firm had revenue of $67.17 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KEQU. Bank of America Corp DE lifted its holdings in Kewaunee Scientific by 2,605.9% in the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock worth $28,000 after buying an additional 443 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Kewaunee Scientific by 18,000.0% in the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock worth $30,000 after acquiring an additional 900 shares in the last quarter. IFP Advisors Inc purchased a new position in Kewaunee Scientific in the fourth quarter valued at about $36,000. Morgan Dempsey Capital Management LLC acquired a new stake in Kewaunee Scientific during the 4th quarter valued at approximately $106,000. Finally, Barclays PLC purchased a new stake in Kewaunee Scientific during the 3rd quarter worth approximately $121,000. 32.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Kewaunee Scientific from a “buy” rating to a “hold” rating in a report on Friday, March 14th.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.